Talazoparib/enzalutamide improves rPFS in mCRPC, regardless of HRR gene mutation status
October 4th 2022The talazoparib/enzalutamide combination was also shown to have benefits in key secondary end points, including prostate specific antigen (PSA) response, time to PSA progression, and overall response rate.
Rucaparib delays disease progression in subgroup of chemotherapy-naïve mCRPC
October 4th 2022“Men with this type of metastatic prostate cancer want to get their genetically targeted therapy as early as possible, and this trial clearly shows the value of rucaparib as a treatment for these men,” said Alan H. Bryce, MD, principal investigator of the TRITON3 trial.
Botox, sacral nerve stimulation highlighted as emerging OAB treatments for elderly patients
September 15th 2022Two studies shared at the 2022 Annual Meeting of the South Central Section of the AUA highlighted onabotulinumtoxinA and sacral nerve stimulation as alternative treatment options for patients older than 70 years with overactive bladder.
Stereotactic ablative radiation effective in systemic therapy–naïve oligometastatic kidney cancer
August 23rd 2022“There has never been a clinical trial for these patients. It is unclear whether these patients should be treated with medication, surgery, or another approach. This represents an unmet medical need,” said Raquibul Hannan, MD, PhD.
FDA grants priority review to olaparib/abiraterone combo for mCRPC
August 16th 2022The application is supported by the phase 3 PROpel trial, which showed that adding olaparib to frontline abiraterone acetate and prednisone/prednisolone significantly improved radiographic progression-free survival in patients with mCRPC.